Reforming the R&D ecosystem for neglected diseases, emerging infectious diseases, and maternal health
Focus Area Overview
Project Team
Sponsors
Focus Area Overview
Reforming the R&D ecosystem for neglected diseases, emerging infectious diseases, and maternal health
The long timelines, high attrition rates, and high costs of global health R&D are impeding the development of new medicines, vaccines, and diagnostics. The Center for Policy Impact in Global Health partnered with colleagues at Open Consultants, the University of KwaZulu-Natal, and Peking University to conduct two studies on reforming the global health R&D ecosystem. The studies focused on product development for neglected diseases, emerging infectious diseases, and maternal health. They explore:
- The potential efficiencies in product development that could be gained from applying artificial intelligence, new clinical trial designs and networks, innovations in manufacturing, regulatory reforms, and new financing mechanisms
- The opportunities and challenges in using monoclonal antibodies and mRNA vaccines in low- and middle-income countries
- The product launches that we are likely to see over the next 20 years, based on what is currently in the R&D pipeline
- The health and economic impact of these launches.
Project Team
- Gavin Yamey, Center for Policy Impact in Global Health
- Marco Schäferhoff, Open Consultants
- Osondu Ogbuoji, Center for Policy Impact in Global Health
- Armand Zimmerman, Center for Policy Impact in Global Health
- Ayodamope Fawole, Center for Policy Impact in Global Health,
- Ernesto Ortiz, Duke Global Health Institute
- Shingai Machingaidze, Global Health Consultant
- Mosa Moshabela, Vice Chair of Research & Innovation at the University of KwaZulu-Natal
- Ming Xu, Dean of the Department of Global Health at Peking University
Sponsors
This project is funded by the Bill & Melinda Gates Foundation.